NEW YORK UBS upgraded Jazz Pharmaceuticals (NASDAQ:JAZZ) to a Buy rating with a $307 price target. The target surpasses the prior analyst consensus of $241.76, signaling substantial upside for the stock.
The upgrade follows Jazz Pharmaceuticals' strong first-quarter 2026 performance. The company reported $1.07 billion in revenue, an increase of 19 percent year-over-year. Adjusted earnings per share reached $6.34, beating the $4.66 consensus estimate.
The company's oncology portfolio drove this growth, expanding by 45 percent. Sales of Xywav, Jazz Pharma's leading sleep disorder treatment, rose 18 percent to $408.2 million in the first quarter. Epidiolex, an epilepsy treatment, contributed $249.8 million, up 15 percent.
Zepzelca, an oncology drug, increased sales 60 percent, reaching $101 million. Its use in combination for first-line small cell lung cancer drove this surge.
A key near-term catalyst for Jazz Pharmaceuticals is the Aug. 25 PDUFA date for zanidatamab. The drug targets first-line HER2-positive gastroesophageal cancer, with analysts projecting peak sales potential exceeding $2 billion.
Jazz Pharma trades at a forward price-to-earnings ratio of 12x. This multiple is attractive compared to its specialty pharmaceutical peers. CEO Renée Galá provided full-year revenue guidance between $4.25 billion and $4.5 billion, saying the quarter positions the company “for an outstanding 2026.”
Despite the positive outlook, Jazz Pharma faces a bear case with several factors. Competition for its oxybate franchise, including generic entrants and Avadel's product, poses a challenge. The company also faces research and development risks and questions regarding capital allocation following past acquisitions.
Jazz Pharmaceuticals carries $5.4 billion in long-term debt. Insider activity also shows executive disposals, with Director Bruce Cozadd selling 6,000 shares at $203.33 on May 1. Many of these sales occurred under pre-arranged 10b5-1 plans.
The broader analyst community maintains a constructive view on JAZZ. The consensus includes six Strong Buy ratings and nine Buy ratings, with only two Hold recommendations. This reflects positive sentiment across Wall Street for the Dublin-based biopharmaceutical firm, with a market capitalization of $14.4 billion.
Other firms have also raised price targets for Jazz Pharmaceuticals. Jefferies increased its target by $5 to $300, while Wells Fargo lifted its target to $300 from $285. TD Cowen also raised its price target to $300, citing strong revenue performance across key products.
